These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19330168)

  • 41. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.
    Hamel S; Bouchard A; Ferrario C; Hassan S; Aguilar-Mahecha A; Buchanan M; Quenneville L; Miller W; Basik M
    Breast Cancer Res Treat; 2010 Feb; 120(1):47-57. PubMed ID: 19301121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
    Wilking U; Karlsson E; Skoog L; Hatschek T; Lidbrink E; Elmberger G; Johansson H; Lindström L; Bergh J
    Breast Cancer Res Treat; 2011 Jan; 125(2):553-61. PubMed ID: 20628810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
    Bernet L; Martinez Benaclocha M; Castera C; Cano Muñoz R; Sevilla F; Alba J; de Dios Barranco J; Cordoba A; Garcia-Caballero T; Hardisson D; de Francisco Hernandez JM; Lazaro JM; Polo L; Riu F; Rezola R; Rojo F; Ruiz I; Hernándiz A; de la Cámara de Las Heras JM; Coupe VM
    Diagn Mol Pathol; 2012 Jun; 21(2):84-92. PubMed ID: 22555091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HER2 Intermediate Breast Cancers.
    Jensen KC; Nielsen TO; Gilks CB; West RB
    Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
    [No Abstract]   [Full Text] [Related]  

  • 51. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
    Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
    Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2 as a target for breast cancer therapy.
    Tagliabue E; Balsari A; Campiglio M; Pupa SM
    Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
    Brunelli M; Manfrin E; Martignoni G; Bersani S; Remo A; Reghellin D; Chilosi M; Bonetti F
    Am J Clin Pathol; 2008 Jun; 129(6):907-11. PubMed ID: 18480007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).
    van de Vijver MJ
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S11-7. PubMed ID: 11167086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2 testing and correlation with efficacy of trastuzumab therapy.
    Fornier M; Risio M; Van Poznak C; Seidman A
    Oncology (Williston Park); 2002 Oct; 16(10):1340-8, 1351-2; discussion 1352, 1355-8. PubMed ID: 12435204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospect for anti-HER2 receptor therapy in breast cancer.
    Brand FX; Ravanel N; Gauchez AS; Pasquier D; Payan R; Fagret D; Mousseau M
    Anticancer Res; 2006; 26(1B):463-70. PubMed ID: 16739306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER2 in breast cancer: a review and update.
    Krishnamurti U; Silverman JF
    Adv Anat Pathol; 2014 Mar; 21(2):100-7. PubMed ID: 24508693
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
    Grimm EE; Schmidt RA; Swanson PE; Dintzis SM; Allison KH
    Am J Clin Pathol; 2010 Aug; 134(2):284-92. PubMed ID: 20660333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.